Search | Clinical Trials Finder

Conditions: Magnetic Resonance Imaging
Interventions: Gadobutrol (Gadavist, BAY86-4875); Drug
Lead sponsor: Bayer; Industry
Eligibility: Up to 2 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Savannah, Georgia • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Ischemic Heart Disease (IHD), Cardiac Magnetic Resonance Imaging, Myocardial Blood Flow
Interventions: Quantitative Myocardial Blood Flow Evaluation, Qualitative Myocardial Blood Flow Evaluation, Gadavist, Vasodilator, Blood draw for the laboratory assessment; Diagnostic Test · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 35 Years to 85 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 13
States / cities: San Francisco, California • Louisville, Kentucky • Boston, Massachusetts + 9 more

Conditions: IC - Interstitial Cystitis
Interventions: Ferumoxytol, Gadobutrol; Diagnostic Test
Lead sponsor: Christopher J Chermansky, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Stage IA Cervical Cancer, Stage IA1 Cervical Cancer, Stage IA2 Cervical Cancer, Stage IB Cervical Cancer, Stage IB1 Cervical Cancer, Stage IB2 Cervical Cancer, Stage IB3 Cervical Cancer
Interventions: Fludeoxyglucose F-18, Gadobutrol, Magnetic Resonance Imaging, Positron Emission Tomography; Other · Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Volunteers
Interventions: Gadobutrol; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Brain Tumor Adult
Interventions: Hyperpolarized 13C-Pyruvate, Gadolinium; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Enhancing Brain Lesions
Interventions: SubtleGAD, Gadobutrol; Device · Drug
Lead sponsor: Subtle Medical; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: Peoria, Illinois • Worcester, Massachusetts • Rochester, Minnesota + 2 more

Conditions: Central Nervous System Neoplasms
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Brain Disease
Interventions: gadoteridol, gadobutrol; Drug
Lead sponsor: Bracco Diagnostics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Teaneck, New Jersey

Conditions: Carotid Stenosis
Interventions: Gadobutrol (Gadovist, BAY86-4875); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 479 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 15
States / cities: Tucson, Arizona • Jacksonville, Florida • Savannah, Georgia + 12 more

Conditions: Breast Cancer
Interventions: Gadobutrol (Gadavist, Gadovist, BAY86-4875); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 9
States / cities: Tucson, Arizona • Oakland, California • Englewood, Colorado + 6 more

Conditions: Known or Highly Suspected Central Nervous System (CNS) Lesion, Known or Highly Suspected Body (Excluding CNS) Lesion
Interventions: Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL, MRI Scan, Gadobutrol; Drug · Diagnostic Test
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Rochester, Minnesota • The Woodlands, Texas

Conditions: Motor Function, Cognitive Function, Contrast Media
Interventions: Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain, Gadolinium Measurements, Gadoxetate disodium, Gadobenate dimeglumine, Gadodiamide, Gadoterate meglumine, Gadobutrol, Gadoteridol; Procedure · Drug
Lead sponsor: Guerbet; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 2,076 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 16
States / cities: Scottsdale, Arizona • New Haven, Connecticut • Chicago, Illinois + 11 more

Conditions: Liver Cirrhosis, Hepatic Cell Carcinoma, Portal Hypertension
Interventions: Injection of a gadolinium contrast agen, Radiotracer Injection, Imaging; Drug · Diagnostic Test
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 99 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Prostate Carcinoma
Interventions: Fluorine F 18 DCFPyL, Gadobenate Dimeglumine, Gadobutrol, Magnetic Resonance Imaging, Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography, Transrectal Ultrasonography Guided Biopsy; Drug · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Brain Diseases, Spinal Cord Diseases
Interventions: Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), OptiMARK~0.1 mmol/kg BW; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 20
States / cities: Sacramento, California • San Diego, California • Jacksonville, Florida + 16 more

Conditions: Cardiomyopathy, Congenital Heart Disease, Cardiovascular Disease, Cardiac Magnetic Resonance Imaging, Acute Myocardial Infarction
Interventions: Siemens MRI scanner; Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 8,781 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2020
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Wayne State University; Other
Eligibility: 20 Years to 59 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Contrast Enhancement in Magnetic Resonance Imaging, Central Nervous System Pathology
Interventions: Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine, Gadoteridol; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 8
States / cities: Indian Wells, California • Orange, California • Miami, Florida + 5 more

Conditions: Coronary Atherosclerosis
Interventions: Cardiac MRI, Contrast, Beta blocker; Device · Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Contrast Enhancement in Magnetic Resonance Imaging
Interventions: Gadobutrol (Gadavist/Gadovist, BAY86-4875); Drug
Lead sponsor: Bayer; Industry
Eligibility: Not listed
Enrollment: 1,602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Diseases
Interventions: Gadoterate meglumine, Gadobutrol; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Glioblastoma
Interventions: Positron Emission Tomography, Computed Tomography, Multiparametric Magnetic Resonance Imaging Scan, Fludeoxyglucose F-18, fluorine F 18 fluorodopa; Procedure · Radiation
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Lesion in Body Region
Interventions: gadopiclenol, Gadobutrol 1 MMOLE/ML Intravenous Solution; Drug
Lead sponsor: Guerbet; Industry
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 7
States / cities: Birmingham, Alabama • Farmington, Connecticut • Chicago, Illinois + 4 more

Search by objective public record fields.

Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)

The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study

Phenotyping Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) by Intravesical Contrast Enhanced - Magnetic Resonance Imaging (ICE-MRI) Bladder Permeability Assay

PET/MRI Scan for the Evaluation of Resectable Stage IA1-IB3 Cervical Cancer

Dynamic Magnetic Resonance Imaging of Human Subarachnoid Space Using Intrathecal Gadolinium Contrast

Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)

MR Image Synthesis With Low Gadobutrol Dose and AI

Comparison of Contrast Agents for MRI Perfusion Analysis in Brain Tumor Patients

Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)

A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis

PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer

Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

Technical Development of Cardiovascular Magnetic Resonance Imaging

Imaging Multiple Sclerosis Lesions Using Magnevist and Gadavist

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems

Coronary Atherosclerosis T1-Weighted Characterization (CATCH)

A Study Called GUS to Understand How Much of the Contrast Agent Gadavist is Used and How Much is Wasted in Two Different Containers (Single-dose Vials and Imaging Bulk Packages ) in a Real-world Setting

Dotarem vs Gadobutrol Contrast for Breast MRI

FDG and FDOPA PET Demonstration of Functional Brain Abnormalities

Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI)